Abstract
Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Current Drug Delivery
Title:Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor
Volume: 10 Issue: 1
Author(s): Jean-Luc Balligand
Affiliation:
Keywords: Beta3-adrenergic receptor, Human, Catecholamines, Heart Failure, Hypertrophy, Myocardial remodeling, Nitric Oxide
Abstract: Beta3-adrenoreceptors (B3AR) are traditionally known as metabolic receptors in adipose tissue, but came into focus in the cardiovascular field after our demonstration of their expression in human cardiac myocytes and endothelial cells, where they mediate endothelium-dependent relaxation of coronary resistance vessels through production of both nitric oxide and endothelium-dependent hyperpolarization factor(s) (EDHF). B3AR are also expressed at the plasma membrane of rodent and human cardiac myocytes. Notably, their expression is increased in several forms of human cardiomyopathies, which raises questions about their adaptive or maladaptive role in myocardial remodelling. To test the hypothesis that they may counteract the adverse effect of B1-B2-AR overactivation, we set out to study the cardiac phenotype of transgenic mice expressing human recombinant B3AR under the cardiac-specific alpha-MHC promoter. While exhibiting no apparent phenotype at basal state, these mice seem protected from hypertrophic remodeling under a variety of stresses, without developing left ventricular dysfunction. Notably, this protection seems to depend on a functional nitric oxide synthase (NOS), as it is abrogated under NOS inhibition. These features can all be recapitulated in homotypic cardiac myocytes cultures in vitro. B3AR transgenic mice may also be protected from fibrosis through a paracrine cross-talk to cardiac fibroblasts. These data suggest a beneficial role of B3AR in myocardial remodeling through attenuation of fibrosis and of excessive cardiac myocyte hypertrophy, while at the same time optimizing perfusion. As B3AR are resistant to homologous desensitization, they are attractive targets for therapeutic interventions in the setting of chronic sympathetic stimulation, as it is prevalent in heart failure and several cardiomyopathies.
Export Options
About this article
Cite this article as:
Balligand Jean-Luc, Beta3-Adrenoreceptors in Cardiovasular Diseases: New Roles for an “Old” Receptor, Current Drug Delivery 2013; 10 (1) . https://dx.doi.org/10.2174/1567201811310010011
DOI https://dx.doi.org/10.2174/1567201811310010011 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Cardiac Specific Overexpression of hHole Attenuates Isoproterenol–Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling
Current Molecular Medicine Biological Activities of Receptor-interacting Protein 140 in Adipocytes and Metabolic Diseases
Current Diabetes Reviews The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Prophylaxis of Cancer
Current Cancer Therapy Reviews Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Cardiac Telocytes
Current Stem Cell Research & Therapy Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Chronic Heart Failure- Potential for Pharmacological Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents